References
[1] Y. Vafai et al., “Racial/Ethnic Differences in Prenatal Supplement and Medication Use in Low-Risk Pregnant Women,” Am. J. Perinatol., Oct. 2020, doi: 10.1055/s-0040-1717097.
[2] C. for D. E. and Research, “FDA recommends avoiding use of NSAIDs in pregnancy at 20 weeks or later because they can result in low amniotic fluid,” FDA, Oct. 2020, Accessed: Mar. 29, 2022. [Online]. Available: https://www.fda.gov/drugs/drug-safety-and-availability/fda-recommends-avoiding-use-nsaids-pregnancy-20-weeks-or-later-because-they-can-result-low-amniotic
[3] E. Collins, “Maternal and fetal effects of acetaminophen and salicylates in pregnancy,” Obstet. Gynecol., vol. 58, no. 5 Suppl, pp. 57S-62S, Nov. 1981.
[4] J. Servey and J. Chang, “Over-the-Counter Medications in Pregnancy,” Am. Fam. Physician, vol. 90, no. 8, pp. 548–555, Oct. 2014.
[5] “Ibuprofen,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK500986/
[6] “Naproxen,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501044/
[7] “Aspirin,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501196/
[8] M. M. Werler, A. A. Mitchell, S. Hernandez-Diaz, and M. A. Honein, “Use of over-the-counter medications during pregnancy,” Am. J. Obstet. Gynecol., vol. 193, no. 3 Pt 1, pp. 771–777, Sep. 2005, doi: 10.1016/j.ajog.2005.02.100.
[9] D. M. Kristensen et al., “Intrauterine exposure to mild analgesics is a risk factor for development of male reproductive disorders in human and rat,” Hum. Reprod. Oxf. Engl., vol. 26, no. 1, pp. 235–244, Jan. 2011, doi: 10.1093/humrep/deq323.
[10] M. S. Jensen et al., “Maternal use of acetaminophen, ibuprofen, and acetylsalicylic acid during pregnancy and risk of cryptorchidism,” Epidemiol. Camb. Mass, vol. 21, no. 6, pp. 779–785, Nov. 2010, doi: 10.1097/EDE.0b013e3181f20bed.
[11] C. A. Snijder et al., “Intrauterine exposure to mild analgesics during pregnancy and the occurrence of cryptorchidism and hypospadia in the offspring: the Generation R Study,” Hum. Reprod. Oxf. Engl., vol. 27, no. 4, pp. 1191–1201, Apr. 2012, doi: 10.1093/humrep/der474.
[12] B. G. Fisher, A. Thankamony, I. A. Hughes, K. K. Ong, D. B. Dunger, and C. L. Acerini, “Prenatal paracetamol exposure is associated with shorter anogenital distance in male infants,” Hum. Reprod. Oxf. Engl., vol. 31, no. 11, pp. 2642–2650, Nov. 2016, doi: 10.1093/humrep/dew196.
[13] D. V. Lind et al., “Maternal use of mild analgesics during pregnancy associated with reduced anogenital distance in sons: a cohort study of 1027 mother-child pairs,” Hum. Reprod. Oxf. Engl., vol. 32, no. 1, pp. 223–231, Jan. 2017, doi: 10.1093/humrep/dew285.
[14] M. L. Eisenberg, T. K. Jensen, R. C. Walters, N. E. Skakkebaek, and L. I. Lipshultz, “The relationship between anogenital distance and reproductive hormone levels in adult men,” J. Urol., vol. 187, no. 2, pp. 594–598, Feb. 2012, doi: 10.1016/j.juro.2011.10.041.
[15] “Acetaminophen,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501194/
[16] O. of the Commissioner, “Don’t Double Up on Acetaminophen,” FDA, Sep. 2020, Accessed: Mar. 29, 2022. [Online]. Available: https://www.fda.gov/consumers/consumer-updates/dont-double-acetaminophen
[17] M. a. M. Rogers and D. M. Aronoff, “The influence of non-steroidal anti-inflammatory drugs on the gut microbiome,” Clin. Microbiol. Infect. Off. Publ. Eur. Soc. Clin. Microbiol. Infect. Dis., vol. 22, no. 2, p. 178.e1-178.e9, Feb. 2016, doi: 10.1016/j.cmi.2015.10.003.
[18] L. Maier et al., “Extensive impact of non-antibiotic drugs on human gut bacteria,” Nature, vol. 555, no. 7698, pp. 623–628, Mar. 2018, doi: 10.1038/nature25979.
[19] C. for D. E. and Research, “FDA Drug Safety Communication: FDA has reviewed possible risks of pain medicine use during pregnancy,” FDA, Sep. 2019, Accessed: Mar. 29, 2022. [Online]. Available: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-has-reviewed-possible-risks-pain-medicine-use-during-pregnancy
[20] Society for Maternal-Fetal Medicine (SMFM) Publications Committee. Electronic address: pubs@smfm.org, “Prenatal acetaminophen use and outcomes in children,” Am. J. Obstet. Gynecol., vol. 216, no. 3, pp. B14–B15, Mar. 2017, doi: 10.1016/j.ajog.2017.01.021.
[21] A. Z. Bauer et al., “Paracetamol use during pregnancy — a call for precautionary action,” Nat. Rev. Endocrinol., pp. 1–10, Sep. 2021, doi: 10.1038/s41574-021-00553-7.
[22] Z. Liew, B. Ritz, C. Rebordosa, P.-C. Lee, and J. Olsen, “Acetaminophen use during pregnancy, behavioral problems, and hyperkinetic disorders,” JAMA Pediatr., vol. 168, no. 4, pp. 313–320, Apr. 2014, doi: 10.1001/jamapediatrics.2013.4914.
[23] E. Stergiakouli, A. Thapar, and G. Davey Smith, “Association of Acetaminophen Use During Pregnancy With Behavioral Problems in Childhood: Evidence Against Confounding,” JAMA Pediatr., vol. 170, no. 10, pp. 964–970, Oct. 2016, doi: 10.1001/jamapediatrics.2016.1775.
[24] M.-H. Chen et al., “Prenatal Exposure to Acetaminophen and the Risk of Attention-Deficit/Hyperactivity Disorder: A Nationwide Study in Taiwan,” J. Clin. Psychiatry, vol. 80, no. 5, p. 18m12612, Sep. 2019, doi: 10.4088/JCP.18m12612.
[25] Z. Liew, M.-A. Kioumourtzoglou, A. L. Roberts, É. J. O’Reilly, A. Ascherio, and M. G. Weisskopf, “Use of Negative Control Exposure Analysis to Evaluate Confounding: An Example of Acetaminophen Exposure and Attention-Deficit/Hyperactivity Disorder in Nurses’ Health Study II,” Am. J. Epidemiol., vol. 188, no. 4, pp. 768–775, Apr. 2019, doi: 10.1093/aje/kwy288.
[26] S. Alemany et al., “Prenatal and postnatal exposure to acetaminophen in relation to autism spectrum and attention-deficit and hyperactivity symptoms in childhood: Meta-analysis in six European population-based cohorts,” Eur. J. Epidemiol., vol. 36, no. 10, pp. 993–1004, Oct. 2021, doi: 10.1007/s10654-021-00754-4.
[27] B. H. Baker et al., “Association of Prenatal Acetaminophen Exposure Measured in Meconium With Risk of Attention-Deficit/Hyperactivity Disorder Mediated by Frontoparietal Network Brain Connectivity,” JAMA Pediatr., vol. 174, no. 11, pp. 1073–1081, Nov. 2020, doi: 10.1001/jamapediatrics.2020.3080.
[28] Z. Liew, B. Ritz, J. Virk, and J. Olsen, “Maternal use of acetaminophen during pregnancy and risk of autism spectrum disorders in childhood: A Danish national birth cohort study,” Autism Res. Off. J. Int. Soc. Autism Res., vol. 9, no. 9, pp. 951–958, Sep. 2016, doi: 10.1002/aur.1591.
[29] Y. Ji et al., “Association of Cord Plasma Biomarkers of In Utero Acetaminophen Exposure With Risk of Attention-Deficit/Hyperactivity Disorder and Autism Spectrum Disorder in Childhood,” JAMA Psychiatry, vol. 77, no. 2, pp. 180–189, Feb. 2020, doi: 10.1001/jamapsychiatry.2019.3259.
[30] C. B. Avella-Garcia et al., “Acetaminophen use in pregnancy and neurodevelopment: attention function and autism spectrum symptoms,” Int. J. Epidemiol., vol. 45, no. 6, pp. 1987–1996, Dec. 2016, doi: 10.1093/ije/dyw115.
[31] R. E. Brandlistuen, E. Ystrom, I. Nulman, G. Koren, and H. Nordeng, “Prenatal paracetamol exposure and child neurodevelopment: a sibling-controlled cohort study,” Int. J. Epidemiol., vol. 42, no. 6, pp. 1702–1713, Dec. 2013, doi: 10.1093/ije/dyt183.
[32] S. L. Rifas-Shiman, A. Cardenas, M.-F. Hivert, H. Tiemeier, A. D. Bertoldi, and E. Oken, “Associations of prenatal or infant exposure to acetaminophen or ibuprofen with mid-childhood executive function and behaviour,” Paediatr. Perinat. Epidemiol., vol. 34, no. 3, pp. 287–298, May 2020, doi: 10.1111/ppe.12596.
[33] M. Etminan, M. Sadatsafavi, S. Jafari, M. Doyle-Waters, K. Aminzadeh, and J. M. FitzGerald, “Acetaminophen use and the risk of asthma in children and adults: a systematic review and metaanalysis,” Chest, vol. 136, no. 5, pp. 1316–1323, Nov. 2009, doi: 10.1378/chest.09-0865.
[34] L. Garcia-Marcos, M. Sanchez-Solis, and V. Perez-Fernandez, “Early exposure to acetaminophen and allergic disorders,” Curr. Opin. Allergy Clin. Immunol., vol. 11, no. 3, pp. 162–173, Jun. 2011, doi: 10.1097/ACI.0b013e3283464c28.
[35] G. Fan, B. Wang, C. Liu, and D. Li, “Prenatal paracetamol use and asthma in childhood: A systematic review and meta-analysis,” Allergol. Immunopathol. (Madr.), vol. 45, no. 6, pp. 528–533, Dec. 2017, doi: 10.1016/j.aller.2016.10.014.
[36] S. Eyers, M. Weatherall, S. Jefferies, and R. Beasley, “Paracetamol in pregnancy and the risk of wheezing in offspring: a systematic review and meta-analysis,” Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol., vol. 41, no. 4, pp. 482–489, Apr. 2011, doi: 10.1111/j.1365-2222.2010.03691.x.
[37] M. Cheelo et al., “Paracetamol exposure in pregnancy and early childhood and development of childhood asthma: a systematic review and meta-analysis,” Arch. Dis. Child., vol. 100, no. 1, pp. 81–89, Jan. 2015, doi: 10.1136/archdischild-2012-303043.
[38] S. C. Dharmage and K. J. Allen, “Does regular paracetamol ingestion increase the risk of developing asthma?,” Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol., vol. 41, no. 4, pp. 459–460, Apr. 2011, doi: 10.1111/j.1365-2222.2011.03716.x.
[39] S. O. Shaheen, C. Lundholm, B. K. Brew, and C. Almqvist, “Prescribed analgesics in pregnancy and risk of childhood asthma,” Eur. Respir. J., vol. 53, no. 5, p. 1801090, May 2019, doi: 10.1183/13993003.01090-2018.
[40] C.-Y. Li et al., “Prenatal exposure to acetaminophen increases the risk of atopic dermatitis in children: A nationwide nested case-control study in Taiwan,” Pediatr. Allergy Immunol. Off. Publ. Eur. Soc. Pediatr. Allergy Immunol., vol. 32, no. 5, pp. 1080–1088, Jul. 2021, doi: 10.1111/pai.13465.
[41] T. Batool et al., “Prenatal and early-life predictors of atopy and allergic disease in Canadian children: results of the Family Atherosclerosis Monitoring In earLY life (FAMILY) Study,” J. Dev. Orig. Health Dis., vol. 7, no. 6, pp. 665–671, Dec. 2016, doi: 10.1017/S2040174416000386.
[42] J. M. Graham, “Update on the gestational effects of maternal hyperthermia,” Birth Defects Res., vol. 112, no. 12, pp. 943–952, Jul. 2020, doi: 10.1002/bdr2.1696.
[43] M. S. Fejzo et al., “Nausea and vomiting of pregnancy and hyperemesis gravidarum,” Nat. Rev. Dis. Primer, vol. 5, no. 1, p. 62, Sep. 2019, doi: 10.1038/s41572-019-0110-3.
[44] N. Nuangchamnong and J. Niebyl, “Doxylamine succinate-pyridoxine hydrochloride (Diclegis) for the management of nausea and vomiting in pregnancy: an overview,” Int. J. Womens Health, vol. 6, pp. 401–409, 2014, doi: 10.2147/IJWH.S46653.
[45] “Doxylamine,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK500620/
[46] A. Einarson, D. Lyszkiewicz, and G. Koren, “The safety of dextromethorphan in pregnancy : results of a controlled study,” Chest, vol. 119, no. 2, pp. 466–469, Feb. 2001, doi: 10.1378/chest.119.2.466.
[47] M. L. Martínez-Frías and E. Rodríguez-Pinilla, “Epidemiologic analysis of prenatal exposure to cough medicines containing dextromethorphan: no evidence of human teratogenicity,” Teratology, vol. 63, no. 1, pp. 38–41, Jan. 2001, doi: 10.1002/1096-9926(200101)63:1<38::AID-TERA1006>3.0.CO;2-6.
[48] “Dextromethorphan,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501456/
[49] R. Silva, J. H. Lee, E. Tweed, and C. P. Paulson, “Clinical inquiries. Is guaifenesin safe during pregnancy?,” J. Fam. Pract., vol. 56, no. 8, pp. 669–670, Aug. 2007.
[50] “Guaifenesin,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501455/
[51] S. Zierler and K. J. Rothman, “Congenital heart disease in relation to maternal use of Bendectin and other drugs in early pregnancy,” N. Engl. J. Med., vol. 313, no. 6, pp. 347–352, Aug. 1985, doi: 10.1056/NEJM198508083130603.
[52] W.-P. Yau, A. A. Mitchell, K. J. Lin, M. M. Werler, and S. Hernández-Díaz, “Use of decongestants during pregnancy and the risk of birth defects,” Am. J. Epidemiol., vol. 178, no. 2, pp. 198–208, Jul. 2013, doi: 10.1093/aje/kws427.
[53] B. A. J. Källén and P. O. Olausson, “Use of oral decongestants during pregnancy and delivery outcome,” Am. J. Obstet. Gynecol., vol. 194, no. 2, pp. 480–485, Feb. 2006, doi: 10.1016/j.ajog.2005.06.087.
[54] M. M. Werler, “Teratogen update: pseudoephedrine,” Birt. Defects Res. A. Clin. Mol. Teratol., vol. 76, no. 6, pp. 445–452, Jun. 2006, doi: 10.1002/bdra.20255.
[55] “Phenylephrine,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501438/
[56] “Pseudoephedrine,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501085/
[57] Q. Li, A. A. Mitchell, M. M. Werler, W.-P. Yau, and S. Hernández-Díaz, “Assessment of antihistamine use in early pregnancy and birth defects,” J. Allergy Clin. Immunol. Pract., vol. 1, no. 6, pp. 666-674.e1, Dec. 2013, doi: 10.1016/j.jaip.2013.07.008.
[58] S. M. Gilboa, E. C. Ailes, R. P. Rai, J. A. Anderson, and M. A. Honein, “Antihistamines and birth defects: a systematic review of the literature,” Expert Opin. Drug Saf., vol. 13, no. 12, pp. 1667–1698, Dec. 2014, doi: 10.1517/14740338.2014.970164.
[59] C. Hansen, T. A. Desrosiers, K. Wisniewski, M. J. Strickland, M. M. Werler, and S. M. Gilboa, “Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997-2011,” Birth Defects Res., vol. 112, no. 16, pp. 1234–1252, Oct. 2020, doi: 10.1002/bdr2.1749.
[60] N. W. Andersson, C. Torp-Pedersen, and J. T. Andersen, “Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes,” JAMA Pediatr., vol. 174, no. 8, p. e201316, Aug. 2020, doi: 10.1001/jamapediatrics.2020.1316.
[61] “Loratadine,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501009/
[62] “Cetirizine,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501509/
[63] “Desloratadine,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501726/
[64] “Chlorpheniramine,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501530/
[65] “Diphenhydramine,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501878/
[66] “Fexofenadine,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK500677/
[67] W. Tongtako, J. Klaewsongkram, T. D. Mickleborough, and D. Suksom, “Effects of aerobic exercise and vitamin C supplementation on rhinitis symptoms in allergic rhinitis patients,” Asian Pac. J. Allergy Immunol., vol. 36, no. 4, pp. 222–231, Dec. 2018, doi: 10.12932/AP-040417-0066.
[68] A. Chanta, J. Klaewsongkram, T. D. Mickleborough, and W. Tongtako, “Effect of Hatha yoga training on rhinitis symptoms and cytokines in allergic rhinitis patients,” Asian Pac. J. Allergy Immunol., Aug. 2019, doi: 10.12932/AP-260419-0547.
[69] C. Vollbracht, M. Raithel, B. Krick, K. Kraft, and A. F. Hagel, “Intravenous vitamin C in the treatment of allergies: an interim subgroup analysis of a long-term observational study,” J. Int. Med. Res., vol. 46, no. 9, pp. 3640–3655, Sep. 2018, doi: 10.1177/0300060518777044.
[70] A. F. Hagel et al., “Intravenous infusion of ascorbic acid decreases serum histamine concentrations in patients with allergic and non-allergic diseases,” Naunyn. Schmiedebergs Arch. Pharmacol., vol. 386, no. 9, pp. 789–793, Sep. 2013, doi: 10.1007/s00210-013-0880-1.
[71] L. Podoshin, R. Gertner, and M. Fradis, “Treatment of perennial allergic rhinitis with ascorbic acid solution,” Ear. Nose. Throat J., vol. 70, no. 1, pp. 54–55, Jan. 1991.
[72] O. S. Palsson, W. Whitehead, H. Törnblom, A. D. Sperber, and M. Simren, “Prevalence of Rome IV Functional Bowel Disorders Among Adults in the United States, Canada, and the United Kingdom,” Gastroenterology, vol. 158, no. 5, pp. 1262-1273.e3, Apr. 2020, doi: 10.1053/j.gastro.2019.12.021.
[73] G. Cullen and D. O’Donoghue, “Constipation and pregnancy,” Best Pract. Res. Clin. Gastroenterol., vol. 21, no. 5, pp. 807–818, 2007, doi: 10.1016/j.bpg.2007.05.005.
[74] H. Li et al., “Gut Microbiota Composition Changes in Constipated Women of Reproductive Age,” Front. Cell. Infect. Microbiol., vol. 10, p. 557515, 2020, doi: 10.3389/fcimb.2020.557515.
[75] A. S. Anderson and M. J. Whichelow, “Constipation during pregnancy: dietary fibre intake and the effect of fibre supplementation,” Hum. Nutr. Appl. Nutr., vol. 39, no. 3, pp. 202–207, Jun. 1985.
[76] J. O. Greenhalf and H. S. Leonard, “Laxatives in the treatment of constipation in pregnant and breast-feeding mothers,” The Practitioner, vol. 210, no. 256, pp. 259–263, Feb. 1973.
[77] H. Jick, L. B. Holmes, J. R. Hunter, S. Madsen, and A. Stergachis, “First-trimester drug use and congenital disorders,” JAMA, vol. 246, no. 4, pp. 343–346, Jul. 1981.
[78] N. Carulli, G. F. Salvioli, and F. Manenti, “Absorption of lactulose in man,” Digestion, vol. 6, no. 3, pp. 139–145, 1972, doi: 10.1159/000197232.
[79] H. Li, P. Zhang, and Y. Xue, “A comparison of the safety and efficacy of polyethylene glycol 4000 and lactulose for the treatment of constipation in pregnant women: a randomized controlled clinical study,” Ann. Palliat. Med., vol. 9, no. 6, pp. 3785–3792, Nov. 2020, doi: 10.21037/apm-20-1674.
[80] I. Neri, I. Blasi, P. Castro, G. Grandinetti, A. Ricchi, and F. Facchinetti, “Polyethylene glycol electrolyte solution (Isocolan) for constipation during pregnancy: an observational open-label study,” J. Midwifery Womens Health, vol. 49, no. 4, pp. 355–358, Aug. 2004, doi: 10.1016/j.jmwh.2004.03.007.
[81] U. Mahadevan and S. Kane, “American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy,” Gastroenterology, vol. 131, no. 1, pp. 278–282, Jul. 2006, doi: 10.1053/j.gastro.2006.04.048.
[82] World Health Organization, “Breastfeeding and maternal medication : recommendations for drugs in the Eleventh WHO Model List of Essential Drugs,” World Health Organization, 2002. Accessed: Mar. 29, 2022. [Online]. Available: https://apps.who.int/iris/handle/10665/62435
[83] N. Acs, F. Bánhidy, E. H. Puhó, and A. E. Czeizel, “Senna treatment in pregnant women and congenital abnormalities in their offspring--a population-based case-control study,” Reprod. Toxicol. Elmsford N, vol. 28, no. 1, pp. 100–104, Jul. 2009, doi: 10.1016/j.reprotox.2009.02.005.
[84] N. Acs, F. Bánhidy, E. H. Puhó, and A. E. Czeizel, “No association between severe constipation with related drug treatment in pregnant women and congenital abnormalities in their offspring: A population-based case-control study,” Congenit. Anom., vol. 50, no. 1, pp. 15–20, Mar. 2010, doi: 10.1111/j.1741-4520.2009.00252.x.
[85] W. F. Baldwin, “CLINICAL STUDY OF SENNA ADMINISTRATION TO NURSING MOTHERS: ASSESSMENT OF EFFECTS ON INFANT BOWEL HABITS,” Can. Med. Assoc. J., vol. 89, pp. 566–568, Sep. 1963.
[86] C. Friedrich et al., “Absence of excretion of the active moiety of bisacodyl and sodium picosulfate into human breast milk: an open-label, parallel-group, multiple-dose study in healthy lactating women,” Drug Metab. Pharmacokinet., vol. 26, no. 5, pp. 458–464, 2011, doi: 10.2133/dmpk.dmpk-11-rg-007.
[87] C. Yang et al., “The effects of psyllium husk on gut microbiota composition and function in chronically constipated women of reproductive age using 16S rRNA gene sequencing analysis,” Aging, vol. 13, no. 11, pp. 15366–15383, Jun. 2021, doi: 10.18632/aging.203095.
[88] J. Jalanka et al., “The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls,” Int. J. Mol. Sci., vol. 20, no. 2, p. E433, Jan. 2019, doi: 10.3390/ijms20020433.
[89] H. K. A. H. Gamage et al., “Fiber Supplements Derived From Sugarcane Stem, Wheat Dextrin and Psyllium Husk Have Different In Vitro Effects on the Human Gut Microbiota,” Front. Microbiol., vol. 9, p. 1618, 2018, doi: 10.3389/fmicb.2018.01618.
[90] T. Karakan, K. M. Tuohy, and G. Janssen-van Solingen, “Low-Dose Lactulose as a Prebiotic for Improved Gut Health and Enhanced Mineral Absorption,” Front. Nutr., vol. 8, p. 672925, 2021, doi: 10.3389/fnut.2021.672925.
[91] Z. Wei, P. Shen, P. Cheng, Y. Lu, A. Wang, and Z. Sun, “Gut Bacteria Selectively Altered by Sennoside A Alleviate Type 2 Diabetes and Obesity Traits,” Oxid. Med. Cell. Longev., vol. 2020, p. 2375676, 2020, doi: 10.1155/2020/2375676.
[92] C. S. Thélin and J. E. Richter, “Review article: the management of heartburn during pregnancy and lactation,” Aliment. Pharmacol. Ther., vol. 51, no. 4, pp. 421–434, Feb. 2020, doi: 10.1111/apt.15611.
[93] D. T. Quach, Y.-L. T. Le, L. H. Mai, A. T. Hoang, and T. T. Nguyen, “Short Meal-to-Bed Time Is a Predominant Risk Factor of Gastroesophageal Reflux Disease in Pregnancy,” J. Clin. Gastroenterol., vol. 55, no. 4, pp. 316–320, Apr. 2021, doi: 10.1097/MCG.0000000000001399.
[94] J. B. G. da Silva, M. U. Nakamura, J. A. Cordeiro, L. Kulay, and R. Saidah, “Acupuncture for dyspepsia in pregnancy: a prospective, randomised, controlled study,” Acupunct. Med. J. Br. Med. Acupunct. Soc., vol. 27, no. 2, pp. 50–53, Jun. 2009, doi: 10.1136/aim.2009.000497.
[95] P. Meteerattanapipat and V. Phupong, “Efficacy of alginate-based reflux suppressant and magnesium-aluminium antacid gel for treatment of heartburn in pregnancy: a randomized double-blind controlled trial,” Sci. Rep., vol. 7, p. 44830, Mar. 2017, doi: 10.1038/srep44830.
[96] V. Strugala, J. Bassin, V. S. Swales, S. W. Lindow, P. W. Dettmar, and E. C. M. Thomas, “Assessment of the Safety and Efficacy of a Raft-Forming Alginate Reflux Suppressant (Liquid Gaviscon) for the Treatment of Heartburn during Pregnancy,” ISRN Obstet. Gynecol., vol. 2012, p. 481870, 2012, doi: 10.5402/2012/481870.
[97] L. A. Magee, G. Inocencion, L. Kamboj, F. Rosetti, and G. Koren, “Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study,” Dig. Dis. Sci., vol. 41, no. 6, pp. 1145–1149, Jun. 1996, doi: 10.1007/BF02088230.
[98] H. Garbis et al., “Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services,” Reprod. Toxicol. Elmsford N, vol. 19, no. 4, pp. 453–458, Apr. 2005, doi: 10.1016/j.reprotox.2004.09.002.
[99] A. Ruigómez et al., “Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes,” Am. J. Epidemiol., vol. 150, no. 5, pp. 476–481, Sep. 1999, doi: 10.1093/oxfordjournals.aje.a010036.
[100] I. Matok et al., “The safety of H(2)-blockers use during pregnancy,” J. Clin. Pharmacol., vol. 50, no. 1, pp. 81–87, Jan. 2010, doi: 10.1177/0091270009350483.
[101] S. Parker, M. Udani, J. S. Gavaler, and D. H. Van Thiel, “Pre- and neonatal exposure to cimetidine but not ranitidine adversely affects adult sexual functioning of male rats,” Neurobehav. Toxicol. Teratol., vol. 6, no. 4, pp. 313–318, Aug. 1984.
[102] “Cimetidine,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 29, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501206/
[103] A. Lalkin et al., “The safety of omeprazole during pregnancy: a multicenter prospective controlled study,” Am. J. Obstet. Gynecol., vol. 179, no. 3 Pt 1, pp. 727–730, Sep. 1998, doi: 10.1016/s0002-9378(98)70072-9.
[104] B. Pasternak and A. Hviid, “Use of proton-pump inhibitors in early pregnancy and the risk of birth defects,” N. Engl. J. Med., vol. 363, no. 22, pp. 2114–2123, Nov. 2010, doi: 10.1056/NEJMoa1002689.
[105] B. A. Källén, “Use of omeprazole during pregnancy--no hazard demonstrated in 955 infants exposed during pregnancy,” Eur. J. Obstet. Gynecol. Reprod. Biol., vol. 96, no. 1, pp. 63–68, May 2001, doi: 10.1016/s0301-2115(00)00388-2.
[106] O. Diav-Citrin et al., “The safety of proton pump inhibitors in pregnancy: a multicentre prospective controlled study,” Aliment. Pharmacol. Ther., vol. 21, no. 3, pp. 269–275, Feb. 2005, doi: 10.1111/j.1365-2036.2005.02306.x.
[107] J. K. Marshall, A. B. Thompson, and D. Armstrong, “Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation,” Can. J. Gastroenterol. J. Can. Gastroenterol., vol. 12, no. 3, pp. 225–227, Apr. 1998, doi: 10.1155/1998/167174.
[108] “Lansoprazole,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 30, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501283/
[109] “Esomeprazole,” in Drugs and Lactation Database (LactMed), Bethesda (MD): National Library of Medicine (US), 2006. Accessed: Mar. 30, 2022. [Online]. Available: http://www.ncbi.nlm.nih.gov/books/NBK501284/
[110] S. H. Koo et al., “Effects of proton pump inhibitor on the human gut microbiome profile in multi-ethnic groups in Singapore,” Singapore Med. J., vol. 60, no. 10, pp. 512–521, Oct. 2019, doi: 10.11622/smedj.2018152.
[111] F. Imhann et al., “Proton pump inhibitors affect the gut microbiome,” Gut, vol. 65, no. 5, pp. 740–748, May 2016, doi: 10.1136/gutjnl-2015-310376.
[112] D. E. Freedberg et al., “Proton Pump Inhibitors Alter Specific Taxa in the Human Gastrointestinal Microbiome: A Crossover Trial,” Gastroenterology, vol. 149, no. 4, pp. 883-885.e9, Oct. 2015, doi: 10.1053/j.gastro.2015.06.043.
[113] M. A. Jackson et al., “Proton pump inhibitors alter the composition of the gut microbiota,” Gut, vol. 65, no. 5, pp. 749–756, May 2016, doi: 10.1136/gutjnl-2015-310861.
[114] A. Vich Vila et al., “Impact of commonly used drugs on the composition and metabolic function of the gut microbiota,” Nat. Commun., vol. 11, no. 1, p. 362, Jan. 2020, doi: 10.1038/s41467-019-14177-z.
[115] S. Weitsman et al., “Effects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes,” Dig. Dis. Sci., vol. 67, no. 1, pp. 224–232, Jan. 2022, doi: 10.1007/s10620-021-06857-y.
[116] E. Dehlink, E. Yen, A. M. Leichtner, E. J. Hait, and E. Fiebiger, “First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study,” Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol., vol. 39, no. 2, pp. 246–253, Feb. 2009, doi: 10.1111/j.1365-2222.2008.03125.x.
[117] E. Hak, B. Mulder, C. C. M. Schuiling-Veninga, T. W. de Vries, and S. S. Jick, “Use of acid-suppressive drugs in pregnancy and the risk of childhood asthma: bidirectional crossover study using the general practice research database,” Drug Saf., vol. 36, no. 11, pp. 1097–1104, Nov. 2013, doi: 10.1007/s40264-013-0093-z.
[118] B. Mulder, C. C. M. Schuiling-Veninga, H. J. Bos, T. W. De Vries, S. S. Jick, and E. Hak, “Prenatal exposure to acid-suppressive drugs and the risk of allergic diseases in the offspring: a cohort study,” Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol., vol. 44, no. 2, pp. 261–269, Feb. 2014, doi: 10.1111/cea.12227.
[119] T. Lai et al., “Acid-Suppressive Drug Use During Pregnancy and the Risk of Childhood Asthma: A Meta-analysis,” Pediatrics, vol. 141, no. 2, p. e20170889, Feb. 2018, doi: 10.1542/peds.2017-0889.
[120] M. Yitshak-Sade, R. Gorodischer, M. Aviram, and L. Novack, “Prenatal exposure to H2 blockers and to proton pump inhibitors and asthma development in offspring,” J. Clin. Pharmacol., vol. 56, no. 1, pp. 116–123, Jan. 2016, doi: 10.1002/jcph.574.